Vera Therapeutics (VERA): next trial readout expected around 2031-05-21
$VERA · Vera Therapeutics, Inc.Trials that could report in the next 12 months: 1BiopharmaCTG
Catalyst timeline
Dates are estimated from each trial's registered completion date — none are FDA decision dates. Counts trials that fit our shared poll budget, not everything VERA is running — see methodology.
- 2031-05-21in 248wA Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
Pipeline
| Program | Phase | Status | Primary completion | Trial |
|---|---|---|---|---|
| A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atac… | Phase 2 | Enrolling By Invitation | 2031-05-21 | NCT06674577 |
| Atacicept in Multiple Glomerular Diseases | Phase 2 | Recruitingstill enrolling patients | NCT06983028 | |
| Monthly Dosing of Atacicept in IgAN | Phase 2 | Active Not Recruitingenrolled, still running | NCT07020923 |
Status-change history
Every ClinicalTrials.gov change recorded for VERA's trials — a running history no other tracker shows.
No status changes detected yet for this ticker.
Frequently asked
When is VERA's next PDUFA date?
No disclosed PDUFA date is currently tracked for this ticker.
What phase is VERA's lead program in?
Phase 2 — recruiting.
Where does this data come from?
ClinicalTrials.gov v2 API (trial status + diffs) and company 8-K/press-release disclosures (PDUFA dates). Every number links to its source.